Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Enterprise Value (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Enterprise Value for 16 consecutive years, with -$293.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 17.44% year-over-year to -$293.5 million, compared with a TTM value of -$293.5 million through Dec 2025, down 17.44%, and an annual FY2025 reading of -$293.5 million, down 17.44% over the prior year.
  • Enterprise Value was -$293.5 million for Q4 2025 at Amicus Therapeutics, down from -$263.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$231.0 million in Q2 2025 and bottomed at -$557.0 million in Q3 2021.
  • Average Enterprise Value over 5 years is -$321.2 million, with a median of -$283.2 million recorded in 2023.
  • The sharpest move saw Enterprise Value dropped 23.73% in 2021, then soared 39.15% in 2022.
  • Year by year, Enterprise Value stood at -$482.5 million in 2021, then skyrocketed by 39.15% to -$293.6 million in 2022, then increased by 2.52% to -$286.2 million in 2023, then increased by 12.67% to -$249.9 million in 2024, then fell by 17.44% to -$293.5 million in 2025.
  • Business Quant data shows Enterprise Value for FOLD at -$293.5 million in Q4 2025, -$263.9 million in Q3 2025, and -$231.0 million in Q2 2025.